Skip to content
Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
ABOUT US
ABOUT US
CAREERS
CONTACT US
PIPELINE
TL1A HLE
PHASE 2
INHBE/ACTIVIN E
IL-13 x TSLP
MYOSTATIN (GDF8)
α4β7 x IL-23
UPDATES
PARTNERSHIP
LICENSING
Press Releases
Updates
Search
Search
All Resources
Press Releases
Videos
All Resources
Press Releases
Videos
Press Releases
Vial Announces Dosing of First Participants in Phase 1 Healthy Volunteer Trial of a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory and Fibrotic Diseases
Read Article
Press Releases
Vial Initiating Phase 1 Healthy Volunteer Trial of VIAL-TL1A-HLE, a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory and Fibrotic Diseases
Read Article
Press Releases
Vial Announces Dosing of First Participants in Phase 1 Healthy Volunteer Trial of a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory and Fibrotic Diseases
Read Article
Press Releases
Vial Initiating Phase 1 Healthy Volunteer Trial of VIAL-TL1A-HLE, a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory and Fibrotic Diseases
Read Article
Clear search querie
